View all news

    TECVAYLI® plus DARZALEX FASPRO® treatment demonstrates 100 percent overall response rate in transplant-eligible patients newly diagnosed with multiple myeloma

    09/19/2025
    Download(opens in new window)PDF

    Multimedia Files:

    View all news
    Questions? Please contact us:
    1-800-950-5089 investor-relations@its.jnj.com